Product Details
Olaparib for Tablets BP
Product Name
:
Olaparib for Tablets BP
Brand Name
:
VEROLAP
Available Strength
:
100 mg
Packing
:
60 Tablets
Pack Insert/Leaflet
:
According To Your Needs
These film-coated tablets meet British Pharmacopoeia standards, supporting targeted treatment across several BRCA-mutated cancers. Oncologists prescribe Olaparib for eligible patients with ovarian, breast, prostate, or pancreatic cancer carrying BRCA mutations.
Olaparib BP (100 mg) is a PARP inhibitor that blocks DNA repair in cancer cells with existing DNA-repair deficiencies, leading to cell death. As a result, it helps control tumor progression across multiple BRCA-mutated cancer types. Because of this targeted mechanism, oncology specialists prescribe it under close supervision as part of an individualized treatment plan. Therefore, hospitals and oncology clinics restrict its use to patients under specialist care.
Key Features
- Meets BP (British Pharmacopoeia) standards for consistent quality
- Delivers targeted PARP inhibition across multiple BRCA-mutated cancer types
- Ensures accurate, validated dosing in every batch
- Manufactured under GMP-compliant, high-alert medication handling protocols
- Intended strictly for use under oncologist supervision
- Restricted to hospital, oncology clinic, and specialist institutional supply